74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Chimerix Inc
Closed
Sector Healthcare
5.15 -0.39
Overview
Share price change
24h
Min
5.12
Max
5.22
Income | -23M |
|---|---|
Sales | 26K |
EPS | -0.26 |
Profit margin | -87,996.154 |
Employees | 72 |
EBITDA | -2M -25M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +79.61 upside |
Next Earnings | 27 Feb 2025 |
|---|
Market Cap | 369M 457M |
|---|---|
Previous open | 5.54 |
Previous close | 5.15 |
News Sentiment
By Acuity
50%
50%
157 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Chimerix Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Chimerix Inc Forecast
Price Target
By TipRanks
79.61% upside
12 Months Forecast
Average 9.25 USD 79.61%
High 12 USD
Low 7 USD
Based on 4 Wall Street analysts offering 12 month price targets forChimerix Inc - Dist in the last 3 months.
Sentiment
By Acuity
157 / 393 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
